JP2016509019A - 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 - Google Patents

高ガラクトシル化抗ｈｅｒ２抗体およびその使用 Download PDF

Info

Publication number
JP2016509019A
JP2016509019A JP2015557533A JP2015557533A JP2016509019A JP 2016509019 A JP2016509019 A JP 2016509019A JP 2015557533 A JP2015557533 A JP 2015557533A JP 2015557533 A JP2015557533 A JP 2015557533A JP 2016509019 A JP2016509019 A JP 2016509019A
Authority
JP
Japan
Prior art keywords
antibody
population
antibodies
produced
epithelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509019A5 (enExample
Inventor
エム ミード，ハリー
エム ミード，ハリー
チェン，リー−ホウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2016509019A publication Critical patent/JP2016509019A/ja
Publication of JP2016509019A5 publication Critical patent/JP2016509019A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
JP2015557533A 2013-02-13 2014-02-13 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 Pending JP2016509019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764488P 2013-02-13 2013-02-13
US61/764,488 2013-02-13
PCT/IB2014/000711 WO2014125377A2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-her2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019238917A Division JP2020125286A (ja) 2013-02-13 2019-12-27 高ガラクトシル化抗ｈｅｒ２抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2016509019A true JP2016509019A (ja) 2016-03-24
JP2016509019A5 JP2016509019A5 (enExample) 2017-03-09

Family

ID=50980322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557533A Pending JP2016509019A (ja) 2013-02-13 2014-02-13 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
JP2019238917A Pending JP2020125286A (ja) 2013-02-13 2019-12-27 高ガラクトシル化抗ｈｅｒ２抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019238917A Pending JP2020125286A (ja) 2013-02-13 2019-12-27 高ガラクトシル化抗ｈｅｒ２抗体およびその使用

Country Status (13)

Country Link
US (1) US20150368357A1 (enExample)
EP (1) EP2956485A2 (enExample)
JP (2) JP2016509019A (enExample)
KR (1) KR20160003634A (enExample)
CN (1) CN105308071A (enExample)
AR (1) AR094781A1 (enExample)
AU (1) AU2014217564B2 (enExample)
BR (1) BR112015019343A2 (enExample)
CA (1) CA2900912A1 (enExample)
IL (1) IL240440A0 (enExample)
MX (1) MX2015010428A (enExample)
TW (1) TW201444870A (enExample)
WO (1) WO2014125377A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534075A (ja) * 2018-06-15 2021-12-09 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料
JP2024161535A (ja) * 2018-06-05 2024-11-19 アムジエン・インコーポレーテツド 抗体依存性細胞貪食の調節

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512014A (ja) * 1998-04-20 2002-04-23 パブロ ウマナ， 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
JP2007533299A (ja) * 2003-10-20 2007-11-22 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジー 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連
JP2009512694A (ja) * 2005-10-21 2009-03-26 ジーティーシー バイオセラピューティックス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
JP2009545325A (ja) * 2006-08-04 2009-12-24 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
JP2010502204A (ja) * 2006-09-10 2010-01-28 グリコトープ ゲーエムベーハー 抗体の発現のための骨髄白血病起源のヒト細胞の使用
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
US20120301919A1 (en) * 2011-05-24 2012-11-29 Agency For Science, Technology And Research Ires mediated multicistronic vectors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
CN101588817B (zh) * 2006-09-10 2013-06-12 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8080415B2 (en) * 2008-09-26 2011-12-20 Eureka Therapeutics, Inc. Modified host cells and uses thereof
BR112015019341A2 (pt) * 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512014A (ja) * 1998-04-20 2002-04-23 パブロ ウマナ， 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP2007533299A (ja) * 2003-10-20 2007-11-22 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジー 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
JP2009512694A (ja) * 2005-10-21 2009-03-26 ジーティーシー バイオセラピューティックス インコーポレイテッド 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
JP2009545325A (ja) * 2006-08-04 2009-12-24 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
JP2010502204A (ja) * 2006-09-10 2010-01-28 グリコトープ ゲーエムベーハー 抗体の発現のための骨髄白血病起源のヒト細胞の使用
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
US20120301919A1 (en) * 2011-05-24 2012-11-29 Agency For Science, Technology And Research Ires mediated multicistronic vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL CHEMISTRY, vol. 84, JPN6018000201, 2012, pages 9655 - 9662, ISSN: 0004108417 *
BIOTECHNOLOGY PROGRESS, vol. 21, JPN6018000203, 2005, pages 1644 - 1652, ISSN: 0003944483 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161535A (ja) * 2018-06-05 2024-11-19 アムジエン・インコーポレーテツド 抗体依存性細胞貪食の調節
JP2021534075A (ja) * 2018-06-15 2021-12-09 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料
JP7273858B2 (ja) 2018-06-15 2023-05-15 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料

Also Published As

Publication number Publication date
EP2956485A2 (en) 2015-12-23
AR094781A1 (es) 2015-08-26
TW201444870A (zh) 2014-12-01
MX2015010428A (es) 2016-04-13
CA2900912A1 (en) 2014-08-21
KR20160003634A (ko) 2016-01-11
AU2014217564A1 (en) 2015-08-27
US20150368357A1 (en) 2015-12-24
JP2020125286A (ja) 2020-08-20
AU2014217564B2 (en) 2018-11-08
WO2014125377A3 (en) 2014-12-04
IL240440A0 (en) 2015-09-24
CN105308071A (zh) 2016-02-03
BR112015019343A2 (pt) 2017-08-22
WO2014125377A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
JP2020125286A (ja) 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
JP2020073550A (ja) 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
JP6433786B2 (ja) 高度ガラクトシル化抗体
JP5328019B2 (ja) 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
JP2016513105A (ja) 改変グリコシル化を有するセツキシマブおよびその使用
AU2012293420B2 (en) Highly galactosylated antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190904